Skip to main content
TECON BIOLOGY Co.LTD logo

TECON BIOLOGY Co.LTD — Investor Relations & Filings

Ticker · 002100 ISIN · CNE000001PZ9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,493 across all filing types
Latest filing 2024-02-08 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002100

About TECON BIOLOGY Co.LTD

https://www.tcsw.com.cn

TECON BIOLOGY Co.LTD operates an integrated industrial chain focused on animal health and nutrition. The company specializes in the research, development, and manufacturing of veterinary biological products, including a comprehensive range of vaccines and diagnostic reagents for livestock. Its operations encompass the production of high-quality animal feed and the management of large-scale breeding programs, with a primary focus on pig farming and meat processing. By leveraging advanced biotechnology and standardized production systems, the company provides comprehensive solutions for livestock management and food safety. Key activities include the formulation of specialized animal nutrition products and the implementation of rigorous biosecurity protocols across its facilities to ensure the quality and reliability of its agricultural outputs.

Recent filings

Filing Released Lang Actions
关于2024年1月份生猪销售简报
Capital/Financing Update Classification · 70% confidence The document is a monthly sales brief for January 2024 from Tian Kang Biological Co., Ltd., detailing sales volume, revenue, and prices of live pigs. It includes month-over-month and year-over-year comparisons, explanations for sales changes, and risk warnings. The document is short (1723 characters) and provides a snapshot of sales performance rather than comprehensive financial statements or detailed management analysis. It is not an annual or quarterly report, nor an earnings release since it lacks key financial highlights or earnings metrics. It is also not a regulatory filing, board change, or capital update. The document fits best as a Capital/Financing Update (CAP) type because it provides operational sales data relevant to company performance and market activity, though it is more of a sales update. Given the options, CAP is the closest match to a sales performance update. Confidence is moderate due to the document's brief nature and focus on sales data rather than full financials.
2024-02-08 Chinese
2023年度业绩预告
Earnings Release Classification · 95% confidence The document is titled as a '2023年度业绩预告' which translates to '2023 Annual Performance Forecast'. It provides estimated financial results for the full year 2023, including expected net profit/loss and earnings per share. The document explicitly states that the data is preliminary, unaudited, and based on internal estimates, with final audited figures to be disclosed in the 2023 Annual Report. It also mentions communication with the accounting firm but no audit has been completed yet. The document is short (1182 characters) and serves as a performance forecast rather than a full financial report. This fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results highlighting key figures and outlook. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and detailed analysis. Therefore, the correct classification is Earnings Release (ER). FY 2023
2024-01-30 Chinese
关于2023年12月份生猪销售简报
Regulatory Filings Classification · 90% confidence The document is a sales brief for December 2023 from Tian Kang Biological Co., Ltd., detailing monthly and cumulative sales volumes and revenues of live pigs. It includes sales data, reasons for sales growth, risk warnings, and a disclaimer that the data is unaudited and for investor reference only. The document is short (1811 characters) and does not contain comprehensive financial statements or detailed financial analysis. It is a periodic sales update rather than a full financial report or earnings release. It does not announce voting results, management changes, or legal matters. It is not a report publication announcement since it contains substantive sales data. The best fitting category is a Regulatory Filing (RNS) as a general regulatory announcement providing interim sales data without full financial statements or earnings highlights.
2024-01-09 Chinese
联合资信评估股份有限公司关于终止天康生物股份有限公司主体及相关债项信用评级的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from a credit rating agency (联合资信评估股份有限公司) regarding the termination of the credit rating for a company's bonds and the company itself. It references the completion of bond maturity and delisting (摘牌), and states that the credit rating will no longer be updated. The document is short (733 characters) and serves as an official notice rather than a full report or detailed financial data. It fits the description of a Regulatory Filing (RNS) as it is a regulatory announcement about credit rating termination and bond delisting, but not a full delisting announcement of stock or a full audit or annual report. It is not a full financial report or earnings release, nor a capital/financing update in the sense of new financing. Therefore, the best classification is Regulatory Filings (RNS).
2023-12-26 Chinese
关于天康转债到期兑付结果及股本变动的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Tian Kang Biological Co., Ltd. regarding the maturity redemption results of its convertible bonds "Tian Kang Convertible Bonds" and the resulting changes in share capital. It includes details such as the redemption amount, dates, bond delisting from the Shenzhen Stock Exchange, and the changes in the company's share capital due to bond conversions. The document is relatively short (1834 characters) and focuses on the completion of bond redemption and capital changes, not on financial performance or detailed financial statements. It is not a full financial report but an announcement about bond maturity, redemption, and share capital changes. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2023-12-25 Chinese
关于兵团国资委签订框架协议的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Tian Kang Biological Co., Ltd. regarding the signing of a framework agreement involving the establishment of a new company with state-owned assets. It details the parties involved, the capital contributions, governance structure, and risk warnings. The document explicitly states that this is a "提示性公告" (a prompt or indicative announcement) about the signing of a framework agreement and does not involve a major asset restructuring or financial report. It is not a full financial report, audit report, or management report, nor is it a regulatory certification or voting result. The document is relatively short (3162 characters) and serves as an announcement of a corporate event related to capital and organizational structure changes. Therefore, it fits best under Capital/Financing Update (CAP).
2023-12-22 Chinese

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.